Lilly Shifts Course With Alzheimer’s Drug Solanezumab
This article was originally published in The Pink Sheet Daily
Executive Summary
In another sign of uncertainty for Alzheimer’s disease drug development, Lilly shakes things up with announcement of design changes for Phase III trial for solanezumab.